This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
DUODOPA (levodopa/carbidopa intestinal gel)
DUODOPA
(levodopa/carbidopa intestinal gel)
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion)
PRODUODOPA
(foslevodopa/foscarbidopa solution for infusion)
Timing matters: Bring device-aided therapies (DATs) early into the conversation1,2
Expert perspective
Introduction to advanced/complex PD
In this 14 minute video Dr Paul Worth, Consultant Neurologist at Addenbrooke’s Hospital in Cambridge, gives an overview of complex/advanced PD, the burden of this on patients and carers, and the 5-2-1 criteria and how it can assist in identifying patients who are in the advanced stages of PD.
What might be the impact of advanced PD on your patients?
Supported by the 5-2-1 criteria, you can:
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson’s medicinal products have not given satisfactory results.3
DUODOPA is indicated for the treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson’s medicinal products have not given satisfactory results.4
DAT=device-aided therapy; PD=Parkinson’s disease.
- Mills J, Martin A. Br J Neurosci Nurs. 2015;11(2):92–7.
- Thanvi BR, Lo TCN. Postgrad Med J. 2004;80(946):452–8.
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) UK Summary of Product Characteristics.
- DUODOPA (levodopa/carbidopa intestinal gel) UK Summary of Product Characteristics.
By clicking the links above you will leave the AbbVie Pro website and be taken to the eMC PI portal website
UK-PRODD-260116. Date of preparation: April 2026
